The Oxford-based gene and cell therapy developer reported a pre-tax loss of £26.0 million for the six months to the end of June, narrowing from £35.7 million a year prior. Driving the improved loss was a 44 per cent top line gain as revenue grew to £73.2 million from £50.8 million. While operating costs improved 10 per cent to £30.3 million from £33.9 million, these gains were more than offset by an increase in administration expenses. It reported an operating Ebitda loss of £15.3 million in 2024. "With our order book more than doubling year-on-year and a strong revenue pipeline, we have good visibility on our growth trajectory and confidence in delivering our near and medium-term financial guidance."